» Articles » PMID: 39971856

Mapping Knowledge Structure and Themes Trends of Ewing Sarcoma: A Text-Mining Study

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2025 Feb 19
PMID 39971856
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ewing sarcoma (ES) is a rare type of cancer that primarily affects children and young adults. In recent years, there have been notable advancements in the treatment of ES due to the introduction of neoadjuvant chemotherapy and targeted therapy, as well as a wealth of related studies in this field published by scholars around the world. However, there is still a lack of a comprehensive report to aid researchers in quickly understanding the knowledge structure and emerging trends of this area.

Materials And Methods: We conducted a comprehensive search in the Web of Science Core Collection for relevant studies published from 2000 to 2023. To conduct a thorough scientometric analysis and create network visualizations, we utilized three different tools, namely, an online analysis platform, CiteSpace, and VOSviewer. These tools enabled us to examine various aspects such as annual publication output; active journals; contributions from countries, institutions, and authors; references; and keywords.

Results: A total of 5163 qualified publications were included. The annual number of publications on ES showed a significant linear growth trend (R = 0.927). The USA stands out as the most productive country. The institution and author that contributed the largest number of papers were University of Texas System and Dirksen U., respectively. As can be seen from highly cited studies and reference analysis and application of Surveillance, Epidemiology, and End Results (SEER) database, preclinical and clinical trials of multiple combination treatment strategies, especially with different approach of immunotherapy such as CAR-T cells or anti-PD-1 antibody for ES, are the primary focus of the current study. Keyword analysis identified several research topics including immunotherapy, tumor microenvironment, microRNA, biomarkers, EWSR1, metastasis, epigenetics, epithelial mesenchymal transition, mesenchymal stem cell, and combination therapy, which have emerged as frontiers in the field and hold significant potential as ongoing research hotspots.

Conclusions: ES is a field that has continued to receive increasing attention in recent years. Harnessing current immunotherapy approaches to improve outcomes of patients with ES is an area of intense interest. This study has provided a comprehensive knowledge map, development landscape, and future directions for ES research, and offered a practical and valuable reference for scholars to obtain better understanding of the current state of research in this field.

References
1.
Esiashvili N, Goodman M, Marcus Jr R . Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol. 2008; 30(6):425-30. DOI: 10.1097/MPH.0b013e31816e22f3. View

2.
Balamuth N, Womer R . Ewing's sarcoma. Lancet Oncol. 2010; 11(2):184-92. DOI: 10.1016/S1470-2045(09)70286-4. View

3.
Orr W, Denbo J, Billups C, Wu J, Navid F, Rao B . Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol. 2012; 19(12):3816-22. DOI: 10.1245/s10434-012-2458-4. View

4.
Grier H, Krailo M, Tarbell N, Link M, Fryer C, Pritchard D . Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348(8):694-701. DOI: 10.1056/NEJMoa020890. View

5.
Womer R, West D, Krailo M, Dickman P, Pawel B, Grier H . Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30(33):4148-54. PMC: 3494838. DOI: 10.1200/JCO.2011.41.5703. View